Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into
Executive Summary
The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.
You may also be interested in...
Novartis Gets First-Mover Advantage With FDA Approval Of Cosentyx For Psoriasis
Secukinumab gets to market before competing IL-17 inhibitors from Lilly and AstraZeneca/Amgen are even filed for approval. Wall Street is expecting blockbuster sales for psoriasis agents that can improve upon the performance of TNF inhibitors.
Novartis’ Secukinumab Sails Through Advisory Panel, Bodes Well For IL-17 Class
Unanimous advisory committee vote positions Novartis’ secukinumab to beat Lilly and Amgen/AstraZeneca competitors to market; panel supportive of Novartis’ preferred dose, letting other dosing issues be further explored post-market.
Secukinumab Phase III Data Look Reassuring Ahead Of Advisory Committee Review
Efficacy results look solid in pair of Phase III trials published in NEJM, but some question whether a double dose adds enough to get approval. Investigators note prevalence of Candida infections in patients on the Novartis drug.